Exosome Therapy for Male Androgenetic Alopecia

Androgenetic alopecia (AGA) is a chronic, progressive condition characterized by gradual miniaturization of hair follicles in a patterned distribution, primarily influenced by genetic susceptibility and androgen-mediated signaling pathways. The condition involves disruption of the hair cycle, particularly shortening of the anagen phase and progressive conversion of terminal hair follicles into vellus-like follicles, ultimately resulting in visible hair thinning and reduced hair density. In addition to its dermatological manifestations, AGA is associated with significant psychological burden, including decreased self-confidence and impaired quality of life.

Current pharmacological interventions mainly aim to slow disease progression rather than fully restore follicular function. However, their limited efficacy and dependency on continuous administration highlight the unmet need for regenerative and disease-modifying therapeutic strategies.

Mesenchymal stem cell-derived exosomes (MSC-Exos) represent a novel class of cell-free biologics with regenerative and immunomodulatory properties. These nano-sized extracellular vesicles contain bioactive molecules such as proteins, lipids, and nucleic acids, which mediate intercellular communication and regulate multiple biological processes. Among different MSC sources, human umbilical cord-derived MSCs are considered to possess advantageous biological characteristics, including higher proliferative capacity, lower immunogenicity, and more stable paracrine activity, making their exosomes particularly suitable for clinical translation.

Experimental studies have demonstrated that MSC-Exos may influence hair follicle biology through multiple complementary mechanisms, including modulation of dermal papilla cell activity, regulation of signaling pathways involved in follicular cycling, enhancement of vascular support within the perifollicular environment, and attenuation of local inflammatory responses. These combined effects may contribute to the reactivation of dormant follicles and support the transition of hair follicles into the anagen growth phase.

This clinical investigation is designed to translate these preclinical findings into a controlled human study setting, aiming to systematically evaluate the therapeutic potential of hUCMSC-derived exosomes for hair regeneration. The study will generate evidence regarding both clinical efficacy and safety profile, providing foundational data for future development of exosome-based regenerative therapies in androgenetic alopecia.